Lupin Ltd
Lupin Ltd (LUPIN) last reported results for the quarter ended Jun 2026, with sales of ₹8,277 crore and net profit of ₹1,417 crore. The stock last traded at ₹1,956, a market capitalisation of ₹89,234 crore, on a P/E of 15.0. Over the past 52 weeks the stock has ranged between ₹1,900 and ₹2,530. Figures are as of 9 Oct 2026 and are not real time.
Lupin Ltd share price and key metrics
- Current price
- ₹1,956
- Market cap
- ₹89,234 cr
- Stock P/E
- 15.0
- Book value
- ₹491
- ROE
- 28.7%
- ROCE
- 29.9%
- Dividend yield
- 0.92%
- 52w high / low
- 2530/1900
Metrics as of 9 Oct 2026. Not real time.
Track Lupin Ltd
Cruxal reads every Lupin Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Lupin Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 13%
- 3 Years
- 19%
- TTM
- 28%
- 10 Years
- 10%
- 5 Years
- 37%
- 3 Years
- 140%
- TTM
- 61%
- 10 Years
- 3%
- 5 Years
- 16%
- 3 Years
- 19%
- 1 Year
- 0%
- 10 Years
- 10%
- 5 Years
- 13%
- 3 Years
- 22%
- Last Year
- 29%
Lupin Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,277 cr, up 32.1% from ₹6,268 cr a year earlier. Net profit was ₹1,417 cr, up 16.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 |
| Expenses | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 |
| Operating profit | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 |
| OPM % | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% |
| Other income | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 |
| Interest | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 |
| Depreciation | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 |
| Profit before tax | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 |
| Tax % | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% |
| Net profit | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 |
| EPS (₹) | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Lupin Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 | 29,967 |
| Operating profit | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 8,160 | 9,538 |
| OPM % | 26% | 20% | 17% | 15% | 17% | 1.3% | 10% | 19% | 23% | 29% | 32% |
| Net profit | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 5,355 | 5,551 |
| EPS (₹) | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 | 120.98 |
TTM is the trailing twelve months to the most recent quarter.
Lupin Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 22,357 |
| Borrowings | 7,966 | 7,143 | 8,496 | 6,305 | 4,783 | 4,158 | 4,542 | 2,922 | 5,448 | 6,616 |
| Other liabilities | 4,749 | 5,300 | 5,423 | 5,968 | 4,844 | 5,340 | 5,794 | 6,539 | 6,327 | 9,082 |
| Total liabilities | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 |
| Fixed assets | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,994 |
| CWIP | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 1,016 |
| Investments | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,670 |
| Other assets | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 22,466 |
| Total assets | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 38,146 |
As reported by the company. Total assets equal total liabilities by construction.
Lupin Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 | 7,334 |
| Cash from investing | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 | -3,865 |
| Cash from financing | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 | -846 |
| Net cash flow | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 | 2,624 |
| Free cash flow | 1,513 | 261 | 706 | 798 | 1,150 | -531 | 436 | 2,732 | 1,347 | 5,527 |
| CFO / operating profit | 117% | 73% | 102% | 84% | 99% | 146% | 124% | 105% | 74% | 105% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Lupin Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% | 30% |
| Debtor days | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 | 86 |
| Inventory days | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 | 303 |
| Days payable | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 | 208 |
| Cash conversion cycle | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 | 181 |
| Working capital days | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 | 28 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Lupin Ltd shareholding pattern
Promoters held 46.85% at Jun 2026, broadly unchanged since Jun 2025. FIIs 22.42% and DIIs 24.65%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.96% | 46.94% | 46.91% | 46.90% | 46.89% | 46.89% | 46.85% | 46.85% |
| FIIs | 21.50% | 22.04% | 21.46% | 21.25% | 20.50% | 21.50% | 21.70% | 22.42% |
| DIIs | 25.10% | 24.73% | 25.41% | 25.55% | 26.56% | 25.58% | 25.32% | 24.65% |
| Government | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.44% | 6.27% | 6.21% | 6.28% | 6.06% | 6.04% | 6.13% | 6.08% |
| No. of shareholders | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 | 2,80,256 | 2,88,931 | 2,90,411 | 3,00,283 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Lupin Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.Company Updatelow impact
- Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USPCompany Updatelow impact
Cruxal's analysis: Lupin Ltd, a large-cap pharmaceutical company with a market cap of approximately 93,058…
Read the full analysis - Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD ManagementCompany Updatelow impact
Cruxal's analysis: Lupin announced the launch of Formoflo-G MDI, a novel fixed-dose triple combination…
Read the full analysis - Lupin Limited completes buyback of 30,559 shares through its subsidiary Multicare Pharmaceuticals Philippines, effectively consolidating ownership and streamlining its corporate structure.Company Updatelow impact
Cruxal's analysis: Lupin Limited has announced the completion of a buyback of 30,559 shares by its wholly…
Read the full analysis - Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- Lupin receives US FDA tentative approval for Apixaban oral suspensionCompany Updatemedium impact
Cruxal's analysis: Lupin Limited has received tentative approval from the U.S. Food and Drug Administration…
Read the full analysis - Lupin Ltd allots 24,111 equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has announced the allotment of 24,111 equity shares to eligible employees upon…
Read the full analysis - Lupin Ltd announces participation in upcoming Analyst/Institutional Investor meetCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has filed an intimation regarding its participation in an analyst and…
Read the full analysis - Lupin Ltd receives ESG rating from CRISIL ESG Ratings & Analytics LtdCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has submitted an intimation regarding its ESG rating assigned by CRISIL ESG…
Read the full analysis - Lupin Ltd allots 30,967 equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has announced the allotment of 30,967 equity shares to employees following the…
Read the full analysis - Lupin Ltd receives ESG rating from ESG Risk Assessment and Insights LimitedCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has provided an intimation under Regulation 30 of the SEBI (LODR) Regulations…
Read the full analysis - Lupin subsidiary VISUfarma enters exclusive license agreement with Visus TherapeuticsCompany Updatemedium impact
Cruxal's analysis: Lupin Ltd's wholly owned subsidiary, VISUfarma B.V. (Netherlands), has entered into an…
Read the full analysis - Lupin Ltd announces the demise of Dr. Sofia Mumtaz, Senior Management PersonnelCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has formally announced the passing of Dr. Sofia Mumtaz, who served as…
Read the full analysis - Lupin receives U.S. FDA approval for Pitolisant TabletsCompany Updatemedium impact
Cruxal's analysis: Lupin has secured U.S. FDA approval for Pitolisant Tablets, a medication used for the…
Read the full analysis - Lupin Limited Reports Record Q1 FY2027 Earnings with Revenue Exceeding INR 8,000 Crore and EBITDA Surpassing INR 2,400 CroreCompany Updatehigh impact
Cruxal's analysis: Lupin Limited delivered a strong performance in Q1 FY2027, reporting total revenue of INR…
Read the full analysis - Lupin receives US FDA approval for Sodium Zirconium Cyclosilicate for oral suspensionCompany Updatemedium impact
Cruxal's analysis: Lupin has received approval from the United States Food and Drug Administration (US FDA)…
Read the full analysis - Lupin Ltd announces participation in Analyst/Institutional Investor meetCompany Updatelow impact
Cruxal's analysis: Lupin Ltd has issued an intimation regarding its participation in an upcoming analyst and…
Read the full analysis - Lupin Limited Reports Strong Q1 FY2027 Financial Results with Significant Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Lupin Limited has released its unaudited financial results for the quarter ended June 30…
Read the full analysis - Lupin Limited releases audio recording of Q1 FY27 earnings callCompany Updatelow impact
Cruxal's analysis: Lupin Limited has formally disclosed the audio recording of its Q1 FY27 earnings call…
Read the full analysis - Lupin Limited Reports Strong Q1 FY27 Results with 33% YoY Revenue Growth and 50% YoY EBITDA ExpansionCompany Updatehigh impact
Cruxal's analysis: Lupin Limited delivered a robust performance for the quarter ended June 30, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.